[HIPEC in ovarian cancer: What should we expect?]
[HIPEC in ovarian cancer: What should we expect?]
Bull Cancer. 2019 May 21;:
Authors: Picard L, Bourgin C, Penault-Llorca F, Beguinot M, Cornou C, Le Bouedec G, Mouret-Reynier MA, Selle F, Pomel C
Abstract
The results of PRODIGE 7 study demonstrate that the use of HIPEC is not beneficial for patients in the treatment of colorectal carcinomatosis. Nevertheless, a recent study published in NewEnglandJournalofMedicine showed that hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival for patients with ovarian peritoneal carcinomatosis. Although, the emergence of targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) results in new standards of treatment in first line or recurrence disease. In this general context, what is the potential interest of HIPEC for the treatment of ovarian carcinoma?
PMID: 31126679 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Picard L, Bourgin C, Penault-Llorca F, Beguinot M, Cornou C, Le Bouedec G, Mouret-Reynier MA, Selle F, Pomel C Tags: Bull Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study